Genetic adjuvants for immunotherapy
US8603458B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 2, 2009 |
| Grant date | Dec 10, 2013 |
| Priority date | — |
| Expiry date | Feb 9, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55538
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells genetically modified with a nucleotide sequence encoding IL-12 and IFN-γ.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.